Citadel Advisors’s Neos Therapeutics, Inc NEOS Stock Holding History

Citadel Advisors’s Portfolio NEOS Stock Details NEOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-18,200	Closed	-$11K	–	14044
2020 Q4	$11K	Buy	18,200 +8,200	+82%	+$5.07K	﹤0.01%	10823
2020 Q3	$5K	Buy	+10,000	New	+$6.8K	﹤0.01%	9966
2019 Q1	–	Sell	-20,000	Closed	-$33K	–	10144
2018 Q4	$33K	Sell	20,000 -2,800	-12%	-$7.86K	﹤0.01%	8598
2018 Q3	$111K	Buy	22,800 +5,600	+33%	+$31.8K	﹤0.01%	8534
2018 Q2	$108K	Buy	+17,200	New	+$128K	﹤0.01%	8205

Citadel Advisors's NEOS Position: Q4 2020 in Review

Citadel Advisors sold out of Neos Therapeutics, Inc (NEOS) in Q4 2020, closing a stake of 10,705 shares — an estimated $6.61K sold.

Citadel Advisors first reported a position in NEOS in Q4 2015 and held it in 10 quarters. The position peaked at $617K in Q3 2017. 37 funds tracked by Wall St. Rank hold NEOS as of Q4 2020.

Citadel Advisors reported no remaining Neos Therapeutics, Inc position as of Q4 2020 after selling out during the quarter.
Citadel Advisors sold 10,705 Neos Therapeutics, Inc shares in Q4 2020, an estimated $6.61K.
Citadel Advisors first reported a position in Neos Therapeutics, Inc in Q4 2015 and held it in 10 quarters.
Citadel Advisors's Neos Therapeutics, Inc position peaked at $617K in Q3 2017.
37 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q4 2020.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.